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The final 25 amino acids of the ectodomain of the P2X receptors,
immediately prior to the second TM (transmembrane domain)
(pre-TM2: Arg304–Ile328 in rat P2X2), are highly conserved.
Whole-cell patch clamp recordings showed that single cysteine
substitutions in the N-terminal half of pre-TM2 (Arg304–Ile314) led
to loss of function at Arg304, Leu306, Lys308 and Ile312. Cysteine
substitutions within this region also resulted in a significant
reduction in the apparent molecular mass of receptors, due
to loss of complex glycosylation at the nearby acceptor site
Asn298, which was not seen for the C-terminal portion of pre-
TM2 (Asp315–Ile328). The reduction in complex glycosylation was
not due to reduced cell-surface presentation, demonstrating that
glycosylation at Asn298 was acting as a sensor of subtle changes
in receptor conformation within the pre-TM2 region. When this
N-glycan site was repositioned closer to the plasma membrane
by mutagenesis (N298S together with G299N, T300N, T301N
or T303N), glycosylation was restored at G299N and T300N, but
was impaired for T301N and completely absent for T303N. These
results suggest that the region in the vicinity of Asp315 is at the
plasma membrane interface and that the N-terminal portion of
pre-TM2 (Arg304–Ile314) is important for the correct conformation
of the receptor at the extracellular face of the membrane.
Key words: ion channel, pre-transmembrane segment 2 (TM2),
topology, scanning cysteine mutagenesis.
INTRODUCTION
P2X receptors are a family of ligand-gated ion channels that
play key roles in diverse physiological processes such as nerve
transmission, control of smooth muscle tone and the response to
inflammation [1]. Functional P2X receptors are trimers. Each of
the three subunits is composed of intracellular N- and C-termini,
two TMs (transmembrane domains) and a large ectodomain [2–4].
One of the most highly conserved parts of the P2X receptor protein
sequence is the final 25 amino acids of the ectodomain which
immediately precedes the second TM (pre-TM2; Arg304–Ile328 in
the rat P2X2 receptor sequence). This region has been proposed
to be a signal transduction module, linking the conformational
change associated with ATP binding to the opening of the channel
pore [5,6]. Residues within this region, in particular Lys308, have
been implicated in both ATP binding and channel gating [7,8].
Previous studies using cysteine mutants within the pre-TM2
region of human P2X1 [5] and alanine mutants within the pre-
TM2 region of rat P2X4 [6] have highlighted the importance of
Arg305, Lys309 and Phe311 in P2X1 (Arg304, Lys308 and Tyr310 in P2X2)
and Tyr315, Gly316 and Arg318 in P2X4 (Tyr310, Gly311 and Arg313 in
P2X2) for optimal channel function. It has also been proposed that
this region of the receptor might contain a membrane-permeant
loop similar to that seen in voltage-gated potassium channels [9].
N-glycosylation of P2X receptors has been shown significantly
to affect both protein folding and function [2,10–13]. Mature
rat P2X2 receptors are glycosylated at Asn182, Asn239 and Asn298;
removal of any single glycan by mutagenesis does not signific-
antly impair receptor function [2], but removal of two or more
glycans leads to incorrect folding and loss of surface presentation
of the receptor [2,13]. In the present study on the func-
tion of rat P2X2 receptors with cysteine substitutions in the pre-
TM2 region, we observed marked differences in the apparent
molecular mass of the mutated receptors when expressed in HEK
(human embryonic kidney)-293 cells. In the present study, we
show that the reasons for these differences have to do with altered
complex glycosylation at Asn298, reflecting a subtle change in the
conformation of the receptor in the pre-TM2 region.
MATERIALS AND METHODS
Molecular and cell biology
The wild-type rat P2X2 cDNA used in the present study has been
described previously [14]; it contains a C-terminal EYMPME
epitope. Single point mutations were introduced into wild-type or
mutant cDNAs using the QuikChange® site-directed mutagenesis
protocol (Stratagene) and the coding regions of each mutant
were fully sequenced. cDNAs corresponding to wild-type or
mutant receptors were transiently transfected into 35 mm dishes
of near-confluent HEK-293 cells using LipofectamineTM 2000
(Invitrogen) according to the manufacturer’s protocol. Transfected
cells were incubated for 48 h (0.1 μg of cDNA/dish) or 24 h (1 μg
of cDNA/dish) to allow protein expression.
Electrophysiology
Whole-cell patch clamp experiments were performed as described
previously [7]. Cells were held at −60 mV, and agonists
were applied for a 2 s duration. EC50 values for agonists were
determined by least-squares curve fitting to the Hill equation:
I/Imax = 1/[1+(EC50/A)n], where I is the current as a fraction of
the maximum (Imax) and [A] is the agonist concentration, and n is
the Hill coefficient.
Abbreviations used: EndoH, endoglycosidase H; HEK, human embryonic kidney; TM, transmembrane domain.
1 To whom correspondence should be addressed at the present address: Manchester Interdisciplinary Biocentre, University of Manchester, 131 Princess
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Solubilization of HEK-293 cell protein and Western blotting
Transfected cells were washed twice in PBS (pH 7.4). Following
pelleting, cells were solubilized in 50 μl of RIPA buffer [20 mM
Tris/HCl (pH 7.4), 150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2 and
protease inhibitors (Complete-EDTA; Roche)] containing 2%
(v/v) Triton X-100 (w/v) for 1 h at 4 ◦C. Insoluble material was
pelleted by centrifugation at 16000 g for 2 min, the protein content
in the supernatant was assayed using the Bio-Rad protein assay kit,
and 10 μg or 1 μg of total protein samples were taken. Samples
were boiled for 2 min at 100 ◦C in SDS/PAGE sample buffer [4%
SDS and 10% (v/v) 2-mercaptoethanol] and loaded on to Nu-
PAGE gels (4–12% gradient gels; Invitrogen) according to the
manufacturer’s protocol. After running, protein was transferred
on to PVDF membranes and Western blotting was performed
according to standard protocols. Both the primary antibody
against the EE-tag (rabbit anti-Glu-Glu; Universal Biologicals)
and the secondary antibody [HRP (horseradish peroxidase)-
conjugated goat anti-rabbit; DAKOCytomation] were used at a
dilution of 1:5000. Bands were visualised using the ECL® plus
kit (GE Healthcare) and Kodak Biomax MS film (Sigma).
Cell-surface biotinylation
Biotinylation was performed at 0 ◦C to prevent internalization of
the label. Transfected cells were washed twice in PBS (pH 7.4),
and once in PBS (pH 8.0). Cells were incubated in 1 mg/ml
sulfo-NHS-biotin (sulfo-N-hydroxysuccinimidobiotin; Pierce) in
PBS (pH 8.0) for 30 min. Unreacted biotin was quenched with
two washes of PBS containing 192 mM glycine and protein was
solubilized and assayed as above. Total protein samples (10 μg)
were taken, and 300 μg of protein was incubated with streptavidin
beads (Pierce) overnight at 4 ◦C to bind cell-surface protein.
Beads were washed three times and samples were boiled for
5 min at 100 ◦C in SDS/PAGE sample buffer to liberate cell-
surface protein. Samples of both total and cell-surface protein
were analysed by Western blotting as above.
EndoH (endoglycosidase H) treatment
Total protein samples were prepared as above, and 100 μg of
samples were incubated with EndoH (Roche; 2 units) for 1 h at
37 ◦C. Following this treatment, 20 μg of equivalent protein was
loaded on to SDS/PAGE gels for Western blotting.
Data analysis
All of the data, where appropriate, are presented as
means +− S.E.M. Statistical analyses were performed using two-
way ANOVA [post-hoc Tukey’s HSD (Honestly Significant
Differences)].
RESULTS
Cysteine mutants in the pre-TM2 region display reduced molecular
mass
The effects of cysteine substitution in the pre-TM2 domain on
functional receptor expression were characterized using whole-
cell patch clamp recording. Figure 1(A) shows the EC50 values
calculated from ATP concentration–current response curves.
Either no currents were observed or the currents were too small to
determine the EC50 values at the mutants R304C, L306C, K308C
and I312C (indicated with #). ATP potency was significantly
reduced for the cysteine mutant at Arg313 (P < 0.01 compared
with wild-type); no significant differences from wild-type were
observed in any other mutants. Therefore most disruption to
channel function was observed for mutants between positions
Arg304 and Ile314 (black bars), whereas mutations in the region
Asp315–Ile328 had little effect on functional receptor (grey bars).
Three mutants (V318C, H319C and G320C) appeared to display
increased ATP sensitivity; however, these values were not
significantly different from wild-type (P > 0.05).
Western blotting with an antibody directed against the C-
terminal EYMPME epitope tag was used to assess the total
protein expression of each cysteine mutant. Several mutants
displayed a reduced apparent molecular mass compared with
wild-type, indicated by a reduction in, or loss of, the upper
band representing protein of higher molecular mass (Figure 1B;
broken lines); for example, the upper band was almost completely
absent in the mutants R304C, L306C, Y310C, I312C and R313C.
Scanning densitometry was used to calculate the percentage of
upper band density relative to total band density (Figure 1C).
The percentage of upper band observed for wild-type P2X2 was
46 +− 1% (n = 36). Cysteine substitutions in the region Arg304–
Ile314 almost all showed a reduced amount of upper band (black
bars), whereas those in the region Asp315–Ile328 did not (grey bars),
with the exceptions of K324C and F325C.
We tested the effects of amino acid substitutions other than
cysteine on the amount of higher molecular mass form observed
in Western blots. P2X2 receptors with K308A, K308C or K308R
have been shown to be significantly impaired in terms of ion-
channel function [7]. However, the proportion of P2X2 receptor
protein running at the higher molecular mass was quite different
for each of these mutants (Figures 2A and 2B). For K308A
the upper band was virtually absent (3 +− 1%, n = 9; P < 0.01
compared with wild-type), for K308C the amount of upper band
was also markedly reduced (11 +− 6%, n = 4; P < 0.01), but for
K308R it was not different from wild-type protein (45 +− 1%,
n = 4; P > 0.05). To ensure that the observed differences in
the amount of upper band were not due to altered cell-surface
expression, we performed cell-surface biotinylation assays to
determine the proportion of mutant receptor expressed at the
cell surface (Figure 2C). At the cell surface, the band profile
of wild-type P2X2 was somewhat altered; it appeared that a
greater proportion of uppermost band was present in this sample.
The mutant K308A was efficiently expressed at the cell surface,
but displayed a complete absence of upper band, demonstrating
that the presence of the upper band was not a requirement for
cell-surface expression. Interestingly, the proportion of upper
band present in the mutant K308C was much greater at the
cell surface than in the total protein sample, suggesting that
the high-molecular-mass form of this mutant was more efficiently
expressed at the cell surface than the lower molecular mass forms.
The cell-surface expression of K308R was identical with wild-
type (results not shown). We quantified these data over several
experiments using scanning densitometry (Figure 2D). For each
mutant, the proportion of receptor at the cell surface was not
significantly different from wild-type, even though the upper band
was partially or fully absent. This data demonstrated that the
reduction in the amount of higher-molecular-mass protein was
not due to reduced cell-surface presentation, but that it reflected
a disruption in protein conformation, the severity of which was
dependent on the identity of the amino acid substituted.
Loss of complex glycosylation at Asn298 underlies the altered
molecular mass
We hypothesized that the loss of the highest molecular mass of
the P2X2 mutants was likely to be due to a reduction in N-linked
glycosylation as a result of altered protein conformation. To test
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Figure 1 Effect of cysteine substitutions in the pre-TM2 region (Arg304–Ile328) on receptor function and glycosylation
(A) Summary of ATP pEC50 values. *P < 0.01 compared with wild-type (WT) for R313C; all other mutants were not significantly different from wild-type (P > 0.05). n = 3–5 for all mutants. #,
either no currents were observed or the currents were too small to allow determination of EC50 values. Dotted lines represent S.D.s above and below the wild-type mean. (B) Sample Western blots of
total protein from HEK-293 cells expressing wild-type (WT) or mutant rat P2X2. Significant reductions in the amounts of upper band may be observed in several mutants. The molecular mass in kDa
is indicated on the left-hand side. (C) Summary of scanning densitometry data (n = 3–36 for each mutant). Each value is expressed as a percentage of the upper band compared with the total band
density. *P < 0.01 compared with wild-type (WT). Wild-type P2X2 was included in every blot to control for variations between experiments and data was recorded only where the band densities were
within the linear range of the sensitivity of the film.
this, we compared the expression of K308A, the N-glycan mutant
N298S, and the double mutant N298S/K308A (Figure 3A). We
observed a significant but differential loss of mass in both
K308A and N298S; the mutant N298S induced a greater loss
of mass than K308A (Figure 3A; lane 2 compared with lane
3). Interestingly, the reduction in mass observed in the double
mutant N298S/K308A was the same as that of N298S (Figure 3A;
lane 4 compared with lane 2). This result demonstrated that
the mutation of Lys308 in the mutant N298S induced no further
loss of mass, implying that the loss of mass seen in the mutant
K308A was most probably due to an alteration in N-glycosy-
lation at Asn298, leading to a reduction in the mass of the glycan
chain.
We reasoned that this might result from loss of complex N-
glycosylation from Asn298, and therefore tested the sensitivity of
wild type P2X2, K308A and N298S to EndoH (Figure 3B). EndoH
only cleaves core, high-mannose N-glycan chains; complex
glycosylation acquired in the Golgi body is resistant to cleavage.
Wild-type P2X2 displayed partial resistance to EndoH treatment
(Figure 3B; lane 2 compared with lane 1). In this blot the
protein loading is lower than that in Figure 3(A), and it can
be observed that wild-type P2X2 expressed in HEK-293 cells
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Figure 2 Effect of different substitutions at Lys308 on receptor glycosylation
(A) Western blot of total protein from HEK-293 cells expressing wild-type (WT), K308A, K308C
or K308R mutant P2X2 receptor. The upper band was absent in K308A, markedly reduced in
K308C, but not different to wild-type in the case of K308R. (B) Summary of the data from
three independent experiments. *P < 0.01 compared with wild-type (WT). (C) Western blot
of biotinylated cell-surface protein from HEK-293 cells expressing wild-type (WT), K308A or
K308C mutant P2X2 receptor. The upper band is absent in K308A, but enriched compared with
total protein in K308C. (D) Summary of the cell-surface biotinylation data from 3–14 independent
experiments. Values are presented as a ratio of cell-surface protein to total protein, normalized
to wild-type (WT). No significant differences in cell-surface expression were observed for any
of the mutants studied.
presents as three bands, reflecting different glycosylation states.
Upon EndoH treatment, the upper band was lost, and a lower
band at approx. 53 kDa (representing fully deglycosylated P2X2)
appeared. Additionally, a band of mass approx. 5 kDa lower
than the uppermost band in the wild-type lane was present,
representing EndoH-resistant protein. This result demonstrates
that a proportion of rat P2X2 expressed in HEK-293 cells acquires
complex glycosylation. In contrast, the mutant N298S was fully
cleaved by EndoH (lanes 5 and 6), demonstrating that, in this
mutant, no complex glycosylation is present, and implying that
Asn298 is likely to be the only site of complex glycosylation
in the rat P2X2 receptor. The loss of mass induced by EndoH
treatment of wild-type P2X2 (Figure 3B; lane 2) was slightly
less than would be expected for the full cleavage of two core
N-glycans (6 kDa). This might reflect anomalous running of this
particular glycoform of P2X2; it might be possible that full EndoH
cleavage was not achieved in this sample or, alternatively, complex
glycosylation might be added to Asn182 or Asn239, but only when
Asn298 contains complex glycosylation. However, the important
finding of this experiment was that K308A was fully cleaved by
EndoH treatment, demonstrating a loss of complex glycosylation
in this mutant, and implying that the loss of the upper band in this
mutation was due to loss of complex glycosylation at Asn298.
Rat P2X2 contains three N-glycan acceptor sequences, which
may or may not be fully used when the protein is expressed in
HEK-293 cells, and characterizing the glycosylation sites might
help us to understand the Western blot profile. We expressed
Figure 3 Difference in molecular mass is due to loss of complex
glycosylation at Asn298
Western blot analysis of total protein from HEK-293 cells expressing wild-type or mutant rat
P2X2 receptor. (A) Removal of the N-glycan chain in the mutant N298S (lane 2) induced a
reduction in molecular mass compared with wild-type (lane 1). Mutation of Lys308 to alanine
(K308A; lane 3) also induced a reduction in mass; however, this was less than that induced
by the mutant N298S. The double mutation N298S/K308A (lane 4) led to the same reduction
in molecular mass as N298S, demonstrating that glycosylation at Asn298 was altered, but not
completely abolished, in the single point mutant K308A. (B) K308A mutation results in loss of
complex glycosylation from Asn298. Following EndoH treatment, partial cleavage of N-glycans
was observed for wild-type P2X2 (lane 2 compared with lane 1), indicating the presence of
complex N-linked glycosylation. However, both point mutants N298S (lane 6 compared with
lane 5) and K308A (lane 4 compared with lane 3) were fully cleaved, indicating that both mutants
had lost complex glycosylation. Similar results were observed in three independent experiments.
(C) Western blot analysis of total protein from HEK-293 cells transiently transfected with 1 μg
of cDNA corresponding to wild-type or mutant P2X2. Protein loading was purposefully low
so as to enable visualization of each glycoform of P2X2. Each of the three N-glycan acceptor
sequences in rat P2X2 (Asn182, Asn239 and Asn298) were mutated with or without K308A and the
changes in molecular mass were analysed. The nature of the three distinct wild-type P2X2
glycoforms (bands a, b and c) was deduced from the numbers of bands present in lanes
corresponding to N182S (lane 3), N239S (lane 5) and N298S (lane 7) and the K308A double
mutants (lanes 4, 6 and 8 respectively). The molecular mass in kDa is indicated on the left-hand
side in (A) and (B) and on the right-hand side in (C).
serine mutants at each site (N182S, N239S and N298S) with or
without the K308A mutation to determine how each site was
utilized (Figure 3C). We intentionally loaded low amounts of
protein (1 μg of protein per lane) to enable visualization of each
glycoform. Mutants N182S (lane 3), N239S (lane 5) and N298S
(lane 7) each displayed a reduction in overall mass. A faint
upper band was also lost from both N182S and N239S when
the mutation K308A was introduced (lanes 4 and 6), whereas
N298S and N298S/K308A were unchanged (lanes 7 and 8). We
argue that this faint upper band represents complex glycosylation
at Asn298 which is lost in the mutant K308A. It was interesting to
note that N182S presented as one major band with a faint upper
band, N239S presented as two major bands with a faint
upper band, and N298S presented as two major bands only.
c© The Authors Journal compilation c© 2008 Biochemical Society© 2008 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited.
Arg304–Ile328 domain and P2X2 conformation 141
This result tells us that the N-glycan site at Asn182 is only
used in a proportion of P2X2 receptors expressed in HEK-
293 cells, whereas Asn239 and Asn298 are always glycosylated
(since mutation of Asn182 leads to a reduction in the number of
bands observed, what has been lost is a site that is only used
in a proportion of receptors). The results of our EndoH studies
(Figure 3B) showed that the complex glycosylation at Asn298 is
only present in a proportion of receptors, and therefore we can
assign each of the three bands observed for wild-type rat P2X2
(Figure 3C, lane 1). Band (a) corresponds to fully glycosylated
protein; band (b) is a mixture of core-glycosylated protein and
protein which lacks glycosylation at Asn182, but contains complex
glycosylation at Asn298; and band (c) corresponds to protein which
is core-glycosylated at Asn239 and Asn298, but which lacks both
glycosylation at Asn182 and complex glycosylation at Asn298.
The distance of glycoslyation site Asn298 from the plasma
membrane
We next examined the effect of moving the glycosylation acceptor
sequence at Asn298 nearer to the plasma membrane. Second
mutations in N298S were made so as to re-introduce the N-glycan
acceptor sequence at positions 299, 300, 301 and 303 (Figure 4A).
All sites were indicated to be good candidates for glycosylation
using NetNGlyc (Expasy), and all constructs displayed channel
function similar to wild-type P2X2 receptors (results not shown).
Analysis of total protein expression by Western blot (Figure 4B;
summary histogram in Figure 4C) showed that moving the
position of the N-glycan acceptor site to position 299 or 300 had no
effect on full glycosylation. In contrast, moving the site to position
301 led to a reduction in full glycosylation of approx. 60%;
this could either represent loss of complex glycosylation at
position 301, or a reduction in the efficiency of core glycosylation
at this residue. Moving the site to position 303 (N298S/T303N)
gave rise to a band profile similar to that of the point mutant N298S
(lane 6 compared with lane 2), implying that there was a complete
absence of glycosylation at this residue. Previous work has
demonstrated that the N-glycosylation acceptor sequence must be
a minimum of 12–14 residues [or 30 Å (1 Å=0.1 nm)] away from
the membrane to be efficiently core glycosylated [15]. Because
core glycosylation was effectively abolished at position 303, we
interpret that this position is 12–14 residues from the membrane,
placing the region around Asp315 at the membrane interface.
DISCUSSION
In the present study we have investigated the effects of introducing
cysteine residues into the pre-TM2 region (Arg304–Ile328) of the rat
P2X2 receptor. This region is highly conserved in all mammalian
P2X receptors [3], and we found that several residues were critical
for efficient receptor function. In particular, cysteine substitution
at Arg304, Leu306, Lys308 and Ile312 gave rise to non-functional
channels, and substitution at Arg313 led to a significant reduction in
ATP potency. Our results correlate partially with those of Roberts
and Evans [5], who showed that cysteine substitutions at Arg305,
Lys309 and Phe311 in the human P2X1 receptor (corresponding to
Arg304, Lys308 and Tyr310 in the rat P2X2 sequence) significantly
impaired receptor function. A study of the pre-TM2 region of rat
P2X4 [6] also showed that alanine substitutions at Tyr315, Gly316
and Arg318 (Tyr310, Gly311 and Arg313 in the rat P2X2 receptor) also
inhibited receptor function. Taken together this work highlights
the importance of the conserved pre-TM2 region centred on
Arg304–Ile314 for correct P2X receptor function.
A striking finding of the present study was that all but one
(A309C) of the cysteine substitutions made in the region Arg304–
Figure 4 N-glycosylation is reduced by decreasing the number of residues
between the glycosylation site (Asn298 or equivalent) and the membrane
(A) Point mutations in P2X2 N298S used to move the position of the N-glycan acceptor sequence
towards the C-terminus by one, two, three or five amino acids. (B) Western blot analysis of
total protein from HEK-293 cells expressing wild-type or mutant P2X2 receptors. Glycosylation
was unaffected by moving the N-glycan acceptor position to 299 or 300, but was reduced at
position 301 and was completely absent at position 303. The molecular mass is indicated on the
left-hand side. (C) Histogram showing values from three independent experiments. *P < 0.01
compared with wild-type.
Ile314 led to substantial loss of complex glycosylation from Asn298.
Asn298 itself is not required for either channel function or cell-
surface presentation of the rat P2X2 receptor [2], and we have
demonstrated that the K308A mutation (which gives rise to loss of
complex glycosylation from Asn298) is expressed at the cell surface
in amounts similar to wild-type P2X2 receptor; this implies that
the loss of complex glycosylation does not indicate loss of cell-
surface expression. The present study therefore suggests that
complex glycosylation at Asn298 is acting as a reporter of a subtle
change in the conformation of the receptor, and does not necess-
arily correlate with loss of ion-channel function (EC50 values of the
mutants T305C, I307C, Y310C, G311C and I314C were not sig-
nificantly different to wild-type, whereas each mutant
construct displayed significant reductions in levels of complex
glycosylation).
It is clear from the present results that most of the mutations
within the pre-TM2 region which affected channel function and/or
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complex glycosylation were N-terminal to Asp315; mutations
within the C-terminal half of pre-TM2 had a much lesser effect.
This suggests that the N-terminal half of pre-TM2 may be in an
environment where tight structural contacts are more important
for correct protein conformation, distinct from the environment
occupied by the C-terminal half. We probed the environment
of the pre-TM2 region by moving the position of the N-
glycosylation acceptor sequence at Asn298 closer to the membrane.
Our finding that Asn298 is approx. 15–17 residues distant from
the membrane would indicate that the region encompassing
Asp315 is at the membrane interface. We do not believe that this
region marks the start of TM2 in the P2X2 receptor, as previous
work demonstrates that the mutant V48C is able to form an
intermolecular disulfide bond with the mutant I328C [17]. Val48
is most probably positioned near the C-terminal end of TM1,
and this would therefore position the N-terminal end of TM2 at
or around Ile328. An intermolecular disulfide bond has also been
demonstrated between the P2X1 mutants K68C and F291C [18];
these residues correspond to Lys69 and Arg291 in the rat P2X2
receptor. Val48 and Lys69 are 21 residues apart, whereas Arg291 and
Ile328 are 37 residues apart; in crude linear terms an additional
16 residues must be fitted inbetween Arg291 and Ile328, and this
is consistent with our observation that Asn298 is 15–17 residues
from the membrane, with approx. 30 residues between Asn298 and
Ile328. It is important to note that Newbolt et al [2] demonstrated
an increase in N-glycosylation in the mutation K324N, using
this result as evidence that Lys324 was on the cytoplasmic side
of the membrane. However, in our studies the double mutant
N298S/K324N appeared similar to N298S alone (results not
shown), implying that glycosylation is not added to the asparagine
residue at position 324 in this mutant.
Such a ‘pairing-off’ of the lengths of the polypeptide chain
external to TM1 and external to TM2 would require approx. 14
‘additional’ amino acids between Asn298 and Ile328. For example,
the region between Asp315 and Ile328 may form a membrane-
parallel structure (for example, an α-helix) which leads into TM2,
thus holding the region Arg304–Ile314 near the membrane. In an
homology model of a fragment of the P2X4 ectodomain based
upon class II aminoacyl-tRNA synthetases, this portion of pre-
TM2 is modelled as a helix extending from TM2 [6]. The residue
Arg318 (corresponding to Arg313 in rat P2X2) is placed towards
the top of this helix, which is inconsistent with our observation
that Arg313 is very close to the membrane interface. One possible
explanation, assuming that the model is reasonably accurate, is
that, as this model did not include the TM2 region of P2X4, there
might be a bend between the helix and TM2, allowing placement
of this helix parallel to the membrane. However, our finding
that cysteine substitutions within the region between Asp315 and
Ile328 were well tolerated, both in terms of channel function and
protein conformation as measured by the degree of complex N-
glycosylation, suggests that this region of the molecule may not
play a significant role in maintaining channel integrity, and is
therefore unlikely to be in such a rigid conformation.
An intriguing possibility is that the region Asp315–Ile328 forms a
membrane-permeant loop, proposed by Brake et al. [9] when
describing the cloning of rat P2X2. This arrangement might
explain why the mutants K324C and F325C displayed impaired
complex glycosylation, because these residues would be placed
at the membrane interface in a similar environment to the Arg304–
Ile314 region, which we have demonstrated to be important
for correct protein conformation and function. To test this
hypothesis, we aimed to probe the environment of the individual
cysteine mutants in pre-TM2 using biotin-maleimide labelling.
Unfortunately, and in contrast with P2X1 [5], wild-type P2X2 was
efficiently labelled by maleimide (results not shown), meaning
that there was no suitable negative control for this experiment.
Roberts and Evans [5] demonstrated that ATP-induced currents
in the human P2X1 receptor mutant G321C (corresponding to
Gly320 in rat P2X2) were markedly impaired upon labelling with
thiol-reactive agents, and suggested that this residue might be
involved in ion permeation. In agreement with this result, we also
saw a similar effect for rat P2X2 G320C labelled with methyl
methanethiosulfonate (results not shown). Furthermore, Cao et al
[7] have recently shown that Lys308 has a critical role in channel
gating: this might be more readily interpreted if the first half of
the pre-TM2 region was very near to the membrane, enabling it to
have a direct influence on the permeation pathway [7]. Whether
or not this ‘loop region’ is truly membrane-permeant might be
tested by looking for intramolecular disulfide bond formation in
double cysteine mutants around Gly320 and residues in TM1 or
TM2.
In summary, we have exploited alterations in complex
glycosylation at Asn298, induced by subtle changes in receptor
conformation, to demonstrate that the region encompassing
Arg304–Ile314 in the rat P2X2 receptor is important both for
maintenance of correct receptor conformation and ion-channel
function, and that it is likely to be positioned near to the
plasma membrane. This finding should contribute to the evolving
understanding of the structure–function relationship of the P2X
receptors.
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